EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Comparing supplemental indications for cancer drugs approved in the US and EU

Jelle Stoelinga, Lourens T Bloem, Massimiliano Russo, Aaron S Kesselheim, William B Feldman

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114330 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Jelle Stoelinga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents, Neoplasms, European Union. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Arnold Ventures LLC, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsNeoplasmsEuropean UnionHumansUnited StatesRetrospective StudiesDrug LabelingUnited States Food and Drug Administration

Stichwörter der Autor:innen

Accelerated approvalConditional marketing authorisationEMAFDARare disease designationSupplemental indications

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; School of…
  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
  • Department of Statistics, the Ohio State University, Columbus, OH, USA.
  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division o…

Förderung

  • Arnold Ventures LLC
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Stoelinga, J., Bloem, L. T., Russo, M., Kesselheim, A. S., & Feldman, W. B. (2024). Comparing supplemental indications for cancer drugs approved in the US and EU. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114330

Vancouver

Stoelinga J, Bloem LT, Russo M, Kesselheim AS, Feldman WB. Comparing supplemental indications for cancer drugs approved in the US and EU. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114330

BibTeX
@article{Stoelinga2024,
  author = {Stoelinga, Jelle and Bloem, Lourens T and Russo, Massimiliano and Kesselheim, Aaron S and Feldman, William B},
  title = {Comparing supplemental indications for cancer drugs approved in the US and EU},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114330}
}
Kostenlos starten →